Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 44
- Registration Number
- NCT04982445
- Locations
- 🇺🇸
GSK Investigational Site, Plano, Texas, United States
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 85
- Registration Number
- NCT04900038
- Locations
- 🇪🇸
GSK Investigational Site, Vigo, Spain
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 62
- Registration Number
- NCT04871113
- Locations
- 🇵🇪
GSK Investigational Site, Lima, Peru
A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 41
- Registration Number
- NCT04857892
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 33
- Registration Number
- NCT04827134
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Low-dose Fostemsavir Extended Release Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 32
- Registration Number
- NCT04757974
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 54
- Registration Number
- NCT04630002
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT04563845
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 687
- Registration Number
- NCT04542070
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 5
- Registration Number
- NCT04507321
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath